Enliven Therapeutics, Inc. (Nasdaq: ELVN) is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics for precision oncology. Headquartered in Burlingame, California, the company leverages deep insights into clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. Enliven's pipeline is anchored by two lead clinical-stage programs: ELVN-001, a selective, ATP-competitive BCR::ABL1 inhibitor being developed for patients with chronic myeloid leukemia (CML), and ELVN-002, a central nervous system (CNS) penetrant, irreversible HER2 inhibitor targeting wild-type HER2 and key mutations in non-small cell lung cancer (NSCLC) and other solid tumors.

Research as of 19 Jun 2026